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Abstract
Epithelial and endothelial cells expressing the primary Coxsackie virus B adenovirus (Ad) receptor
(CAR) and integrin coreceptors are natural targets of human Ad infections. The fiber knob of species A,
C, D, E and F Ad serotypes binds CAR by mimicking the CAR-homodimer interface, and the penton
base containing arginine-glycine-aspartate (RGD) motifs binds with low affinity to alphav integrins
inducing cell activation. Here, we generated seven different genetically modified Ad vectors with RGD
sequences inserted into the HI loop of fiber knob. All mutants bound and infected CAR and alphav
integrin-positive epithelial cells with equal efficiencies. However, the Ads containing two additional
cysteines, both N and C terminals of the RGD sequence (RGD-4C), were uniquely capable of
transducing CAR-less hematopoietic and nonhematopoietic human tumor cell lines and primary
melanoma cells. Both binding and transduction of RGD-4C Ad were blocked by soluble RGD peptides.
Flow cytometry of cell surface integrins and virus binding to CAR-less cells in the presence of
function-blocking anti-integrin antibodies indicated that the alphavbeta5 integrin, but not alphavbeta3,
alphaIIbbeta3 or beta1,alpha5 or alpha6-containing integrins served as a functional transduction receptor
of the RGD-4C Ads. However, in cells with low levels of alphavbeta5 integrin, the function-blocking
anti-alphavbeta5 antibodies were not effective, unlike soluble RGD peptides. Collectively, our data
demonstrate that the alphavbeta5 integrin is a functional transduction receptor of RGD-4C Ads in the
absence of CAR, and that additional RGD receptors are targets of these viruses. The RGD-4C vectors
further extend the tropism of Ads towards potential human therapies.
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Abstract
Epithelial and endothelial cells expressing the primary Coxsackie virus B
Adenovirus (Ad) receptor (CAR) and integrin coreceptors are natural targets
of human Ad infections.  The fiber knob of species A, C, D, E and F Ad
serotypes binds CAR by mimicking the CAR-homodimer interface, and penton
base containing arginine-glycine-aspartate (RGD)-motifs binds with low
affinity to av integrins inducing cell activation.  Here, we generated seven
different genetically modified Ad vectors with RGD-sequences inserted into
the HI loop of fiber knob.  All mutants bound and infected CAR and av
integrin-positive epithelial cells with equal efficiencies.  However, the Ads
containing two additional cysteines both N- and C-terminal of the RGD-
sequence (RGD-4C) were uniquely capable of transducing CAR-less
hematopoietic and non-hematopoietic human tumour cell lines and primary
melanoma cells.  Both binding and transduction of RGD-4C Ad was blocked
by soluble RGD-peptides.  Flow cytometry of cell surface integrins and virus
binding to CAR-less cells in the presence of function-blocking anti-integrin
antibodies indicated that the avb5 integrin, but not avb3, aIIbb3 or b1, a5 or
a6-containing integrins served as a functional transduction receptor of the
RGD-4C Ads.  However, in cells with low levels of avb5 integrin the function-
blocking anti-avb5 antibodies were not effective, unlike soluble RGD-peptides.
Collectively, our data demonstrate that the avb5 integrin is a functional
transduction receptor of RGD-4C Ads in the absence of CAR, and that
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additional RGD-receptors are targets of these viruses.  The RGD-4C vectors
further extend the tropism of Ads towards potential human therapies.
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Introduction
Human Adenoviruses (Ads) infect numerous tissues and cell lines with
excellent efficiencies.  Accordingly, replication-defective Ad vectors carrying
therapeutic genes have been employed for a wide variety of gene therapy
applications1 and conditionally replicating Ads are being developed for cancer
treatments2.  In human epithelial and other permissive cells, efficient entry of
the species C Ads, including the currently used Ad2 and Ad5, depends on the
presence of the Coxsackie virus B Ad receptor (CAR)3,4 and of secondary
integrin coreceptors5,6.  Integrin binding of the conserved RGD-motif of the
capsid protein penton base activates virus uptake by receptor-mediated
endocytosis using clathrin-coated pits7-9.  Although there are at least eight
different cell surface integrins recognising RGD, including the five av integrins
avb1, avb3, avb5, avb6, avb8 and the aIIbb3, a3b1 and a5b1 integrins10, only
avb3 and avb55, a5b111 and avb112,13 have been implicated as Ad secondary
receptors.
Both primary and secondary Ad receptors are required for efficient infections
of different types of cells, such as polarised airway epithelial cells14-17, brain
tissue18, skeletal muscle19,20, endothelial and smooth muscle cells21, and
certain hematopoietic cells including human leukocytes22-24 and human
monocyte-derived dendritic cells (DCs)25-27.  However, the expression levels of
CAR were found to vary considerably among tumours of different origins,
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including hematopoietic malignancies28-32, melanoma cell cultures33, bladder
cancer cells34, head and neck cancer35, and ovarian tumours36.
To overcome a limited expression of natural Ad receptors, host range
modifications of potentially therapeutic vectors have been proposed (for a
review see37).  One promising approach to expand the viral tropism is to
genetically incorporate targeting ligands into capsid proteins, such as the fiber
knob, the penton base, hexon or the stabilising protein!IX, as described
recently38.  Targeting ligands included the integrin-binding arginine-glycine-
aspartate (RGD) motif flanked on both sides by cysteine-
aspartate/phenylalanine-cysteine residues (RGD-4C)39 which had been
inserted either together with a 10-amino-acid linker at the carboxy terminus of
the Ad5 fiber40 or into the fiber HI loop41.  A similar RGD-sequence was also
introduced into a hypervariable region of the Ad5 hexon and this conferred a
fiber knob-independent transduction of epithelial cells42.  This all suggests that
the ablation of the native viral tropism and true retargeting may be feasible.
The precise knowledge of the transduction pathway is required for transferring
any modified viral vector into the clinic.  Given that the RGD-dependent entry
of natural species C Ad vectors is rather well characterised in terms of viral
endocytosis and cell activation (for recent reviews, see43,44), we decided to
generate a panel of fiber-HI-loop-modified Ads by genetic insertions of RGD-
sequences.  All viruses infected CAR and avb5 positive cells equally well, but
only the Ads bearing the constrained RGD-4C motif transduced CAR-negative
cells in an RGD-dependent manner.  Our data indicate that RGD-4C inserted
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into the HI-loop targets to avb5 integrin and thereby effectively transduces
cells lacking the primary receptor CAR.
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Materials and Methods
Cell culture:
Jurkat (acute T-cell leukaemia), U937 (D) and (H) (monocytic lymphoma,
different sublines), Daudi, Ramos and Raji (Burkitt’s B-lymphoma), and K562
(chronic myelogenous leukaemia) cells were grown in RPMI 1640 plus 10%
foetal calf serum (FCS).  HL-60 (promyelocytic leukaemia) and THP-1 (acute
monocytic leukaemia) cells were cultured in Iscove modified Dulbecco
medium (IMDM) plus 10% FCS as described45.  The human embryonic
retinoblast cell line 911 cells was received from Fallaux et al.46 and grown in
Dulbecco’s modified Eagle’s medium (DMEM) plus 10% FCS.  The primary
melanoma short time cultures M950822, M951004, M950504, M961205,
M960104, and M950710 were obtained from R. Dummer (Department of
Dermatology, University of Zürich) and were grown in DMEM plus 10% FCS47.
The human embryonal rhabdomyosarcoma (RD) cell line was obtained from
R. Eckner (Institute of Molecular Biology, University of Zürich).  Freshly
isolated, primary human umbilical vein endothelial cells (HUVEC) were a kind
gift of L. Jornot (Respiratory Division, University Hospital Genève, Genève,
Switzerland) and were grown in RPMI 1640 plus 10% FCS, 15!µg/ml
endothelial cell growth supplement, 90!µg/ml heparin, and 25!mM HEPES (pH
7.0).  Primary human fibroblasts isolated from human foreskin were kindly
provided by J. Liu (Department of Dermatology, University Hospital, Zürich,
Switzerland).  The A549 human lung carcinoma cell line was received from P.
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Sonderegger (Biochemical Institute, University of Zürich) and was grown in
DMEM plus 10% FCS.  All cell lines were routinely screened for the absence
of mycoplasma contamination.  Monocyte-derived dendritic cells (DCs) were
generated as described previously48.  Briefly, DCs were isolated from buffy
coat of blood samples taken from healthy donors and incubated for 7 days in
the presence of interleukin-4 (IL-4) and granulocyte-macrophage colony
stimulating factor (GM-CSF).  To induce maturation, a cocktail containing IL-4,
GM-CSF, IL-1b, IL-6 and tumour necrosis factor a was added at day!7.  Such
cultures consisted of approximately 95% mature, loosely adherent DCs
positive for CD83 surface expression.
Construction of recombinant fiber-modified Ad
The AdCMV-eGFP vectors containing modified fibers (D-K) or wt fiber (Z) are
listed in Table!1.  They were constructed in two steps.  In a first step, the fiber
modifications were introduced into AdMLP-lacZ, an E1/E3 deletion mutant
derived from Ad5dl324 containing the b-galactosidase gene in the E1 region
under the control of the Ad mayor late promoter (MLP).  This was
accomplished using either homologous recombination in 911 helper cells (for
AdCMV-eGFP-D)49 or ligation (AdCMV-eGFP E-K and Z)50.  As the eGFP
reporter turned out to be more convenient for transgene expression analysis,
homologous recombination in 911 cells was used to exchange the MLP-lacZ
reporter system with the CMV-eGFP transgene in all of the eight constructs.
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Thus, the modifications of the fiber gene (position 31,168-32,910) were
introduced into AdMLP-lacZ making use of a transfer plasmid pAdMlu-frg,
containing the Ad5 Mlu!I-right end 9,737!bp fragment including the whole
open reading frame of the fiber gene (1,743!bp).  pAdMlu-frg was constructed
by cloning a PCR-derived (primers 5’!CGGAATTCATCATCAATAATATACCT-
TATTTTGG!3’ and 5’!CGCGGATCCGCGGGAAGAGCTGGAAGAACC!3’)
Avr!II 472!bp Ad5 right end fragment together with the adjacent 9,265!bp
Avr!II–Mlu!I fragment into an Eco!RI–Bam!HI-restricted pBluescript KS
(Stratagene, La Jolla, USA).  Introduction of the seven genetic alterations
(Table!1) into the HI loop were achieved by site-directed mutagenesis using
overlapping PCR-products as intermediate templates.  Mutation D was
generated by the use of mutagenesis primers 5’!AACGGTCATGCCATTCGC-
GGCGACACCTTTGCCACAGCATACTCTATGTCATTTTCATG!3’ and 5’!TA-
TGCTGTGGCAAAGGTGTCGCCGCGAATGGCATGACCGTTTAGTGTAAT-
GGTTAG !3’ in combinat ion with f lanking pr imers SM1
(5’!CGGAATTCATATGACACGGAAACCGG!3’) and SM2 (5’!CCGGGATCCT-
GCAGGACGGAGCGG!3’) respectively, which contained the unique
restriction sites Nde ! I and Sse!8387I used for subcloning the 2,202!bp
fragment.  Similarly, mutation E was introduced using mutagenesis primers
5’!GCACTGCAAAAGCAGTCGCCGCGGCAGTCGCAACCGTTTAGTGTAA-
TGGTTAGTG!3’ and 5’!AACGGTTGCGACTGCCGCGGCGACTGCTTTTGC-
AGTGCATACTCTATGTCATTTTC!3', mutation F was introduced using 5’!GA-
CACACGCGGAGACGCATACTCTATGTCATTTTCATG!3’ and 5’!TATGCGT-
CTCCGCGTGTGTCTCCTGTTTCCTGTG!3' primers, mutation G was
Nagel et al.
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introduced using 5’!CAGGAACGCGGAGACACAACTCCAAGTGC!3’ and
5’!GTTGTGTCTCCGCGTTCCTGTGTACCGTTTAGTG!3' primers, mutation H
was introduced using 5’!CTAAACCGCGGAGACGAAACAGGAGACACAACT-
CC!3’ and 5’!GTTTCGTCTCCGCGGTTTAGTGTAATGGTTAGTGTTAC!3'
primers, mutation I was introduced using 5’!ACGAACGCGGAGACACACGC-
GGAGACGCATACTCTATGTCATTTTCATG!3’ and 5’!GCGTGTGTCTCCGC-
GTTCGTCTCCGCGGTTTAGTGTAATGGTTAGTGTTAC!3' primers, and
mutation K was introduced using 5’!ACAACTTGTGACTGCCGCGGAGACTG-
TTTCTGCCCAAGTGCATACTCTATGTC!3’ and 5’!CTTGGGCAGAAACAGT-
CTCCGCGGCAGTCACAAGTTGTGTCTCCTGTTTCCTG!3' primers.  All
sequence alterations were verified by sequencing the resulting transfer
plasmids.
The AdMLP-lacZ-D virus was generated by homologous recombination in 911
helper cells after transfecting the Spe!I-restricted viral genomic AdMLP-lacZ
DNA (lacking 7,047!bp of the right end) together with the linearised pAdMlu-
frg-D. The region of homologous sequence encompasses 2,690!bp.  The
residual six fiber-mutated AdMLP-lacZ-E, -F, -G, -H, -I, -K were generated by
ligation of the Spe!I-restricted viral genomic AdMLP-lacZ DNA with the Spe!I-
restricted pAdMlu-frg-E, -F, -G, -H, -I, and -K, respectively.  Exchange of the
reporter system was accomplished using the left end transfer plasmid
pAdCMV-eGFP derived from pEGFP-N1 (Clontech, Palo Alto, USA) and
Cla!I-restricted viral DNA.  CsCl purification and determination of viral titers
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were performed as described previously33.  Viral DNAs from all seven
constructs were purified and resequenced to confirm HI-loop alterations.
Immunoreagents and flow cytometric analysis
Table!2 lists references and sources of the antibodies used for the
characterisation of integrins.
For cytofluorometric analysis of adherent cells, subconfluent cells were
washed with PBS and detached by treatment with PBS-20!mM EDTA.
Approximately 106 cells were incubated with either 50!µl of hybridoma
supernatant or 1!µg of various antigen-specific antibodies in 250!µl of
balanced salt solution (BSS) (0.14!M NaCl, 1!mM CaCl2, 5.4!mM KCl, 0.8!mM
MgSO4, 0.3!mM NaH2PO4, and 0.4!mM KH2PO4 pH 6.9) containing 5% FCS
on ice for 30!min.  If unlabelled primary antibodies were used, cells were
washed by pelleting in BSS-2% FCS, incubated with 1!µg of phycoerythrin-
labelled secondary conjugates, and washed again before cytofluorometric
analysis (Epics XL; Coulter, Miami, USA) was performed with 10,000 viable
cells per sample.
For eGFP expression analysis, cells were infected with fiber-modified and
unmodified Ads containing the eGFP reporter at multiplicities of infection
(MOI) of 0.1, 1, 10 and 100.  Two days post infection, cells were detached,
washed and analysed as described above.  The GRGDSP peptide and the
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GRGESP control peptide (5!mM each, Biochemical Institute, University of
Zürich, Switzerland), were added to the cells prior to adding the reporter virus.
Labelling of Ads with [35S]methionine
[35S]methionine-labelled virus was prepared in 911 helper cells.  About 6 x 107
cells were infected with AdCMV-eGFP-E, -K, and –Z, respectively, at an MOI
of 10 in DMEM 2% horse serum.  Unbound virus was washed off after 10!h
and medium was replaced with methionine-free MEM containing Fetaclone III
media additive (Hyclone, Logan, USA).  Each cell/virus batch was
subsequently labelled with 1!mCi of Trans 35S-label (ICN Biomedicals, Irvine,
USA) in 15!ml for 24!h, when the medium was supplemented with an equal
volume of complete medium for an additional 20!h.  Viruses were released
from cells by 3 cycles of freeze thaw and extraction with Freon 113 (Chemie
Brunschwig, Switzerland) and purified by two subsequent centrifugations
through two cushions of 1.2 and 1.45!g/ml CsCl in 50!mM Tris-HCl (pH!8.0) as
described51.  Viruses were dialysed against PBS and stored in aliquots at
–80°C.  Specific infectivity was determined to be 0.4 x 10-3 cpm/pfu for
AdCMV-eGFP-E and AdCMV-eGFP-Z, and 0.7 x 10-3 cpm/pfu for AdCMV-
eGFP-K.
Virus binding assays
For binding studies, 5!x!105 cells were incubated in 200!µl ice-cold binding
medium (PBS plus RPMI-10% FCS, 1:1 mix) for 2!h with radio-labelled
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viruses at MOIs in the range of 100-300, except for M950504 cells where
2!x!105 cells were used.  Binding experiments were performed in the presence
or absence of CARex-Fc and CTLA4-Ig45 (2.0!µg each), circular RGD and
linear GSH peptides (0.4!mM), anti-integrin and control antibodies (10!µg).
The cells were washed three times by pelleting in binding buffer, dissolved in
1!ml 0.1% SDS, and the cell-associated radioactivity was determined  by
scintillation counting as described52.
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Results
Construction of fiber-modified RGD-Ads
To extend the Ad tropism, the integrin-binding RGD-motif has been inserted
into several viral capsid proteins, including the fiber HI loop41.  The most
effective motif was a disulphide restrained RGD-4C nonapeptide that was
previously shown to bind with high affinity to both avb3 and avb5 integrins39.
We speculated that the particular context in which the RGD motif is presented
to integrins will also influence the binding and transduction.  We therefore
constructed a series of seven fiber-HI-loop-modified Ads by genetic insertion
of sequences containing the integrin-binding peptide motif RGD, including the
RGD-4C Ad vector (AdCMV-eGFP-K, AdK) described by others (Table!1)41.
In the AdK construct, the RGD-4C peptide had been inserted into the HI-loop,
increasing the HI-loop by seven amino acids.  In contrast, the AdCMV-eGFP-
E (AdE) construct contained the same peptide, but parts of the wild type (wt)
sequence were replaced maintaining the HI-loop length of 13 amino acids.  In
constructs AdCMV-eGFP-D (AdD), -F (AdF), -G (AdG), -H (AdH), and -I (AdI),
the surrounding sequences of the linear RGD sequence motif were varied.
The HI loop of AdD contained three and four amino acids flanking the RGD of
the Ad5 penton base.  In AdF, AdG and AdH the RGD sequence was
introduced either on the C-terminal, the central or N-terminal side of the HI
loop, leaving the residual HI sequence unchanged.  In AdI, all three RGD
motifs of AdF, AdG and AdH were introduced simultaneously.  Construct
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AdCMV-eGFP-Z (AdZ) contained the wt fiber sequence.  All constructs  were
first prepared to contain lacZ as a reporter gene and were later modified to
contain the eGFP reporter gene for cytofluorometric expression assays.  It
was possible to rescue infectious viruses from all the constructs.  The viral
titers (pfu) were evaluated by standard plaque-formation assays on 911 cells
and compared to the virus concentrations expressed as particles per ml
(Table!1).  The infectivity index (pfu per particle) varied between 0.015 and
0.069, corresponding to a range of 67 to 14 particles per pfu.  Of note is that
the RGD-4C AdE had the highest specific activity of all viruses.
RGD-4C Ads efficiently transduce CAR-negative avb5 integrin expressing
cells
We first assessed the transduction potential of the RGD-modified  Ad vectors
on adherent epithelial A549 cells and primary HUVECs.  These cells were
CAR-positive and expressed high levels of surface avb5 over avb3 integrins
(Table!3), as determined by either cytofluorometric analysis or by Western
blotting for CAR45 and by cytofluorometric analysis using specific anti-integrin
antibodies (Table!2).  Quantitative eGFP expression analyses indicated that
both A549 and HUVECs were equally well transduced by the seven different
Ad vectors, independent of whether they carried an extra RDG motif in their
fiber knob (Fig.!1).  The same results were obtained with the CAR and av
integrin positive rhabdosarcoma cells RD and the primary human melanoma
cells M951004 (not shown).  Likewise, eGFP expression by any of the RGD-
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modified Ads was very similar to control wt fiber virus in CAR- and av-integrin
positive hematopoietic cells, such as the leukaemia K562, Raji and Jurkat
cells (Table!4, and not shown).  This suggests that the affinity of the RGD-Ads
to CAR is higher than for RGD-recognising surface receptors.  Also, for the
hematopoietic cells, a much lower plateau level of maximal expression was
obtained, when compared to nonhematopoietic cells.
A different picture emerged when we analysed the transduction of CAR-
negative nonhematopoietic melanoma cells and primary fibroblasts (Fig.!2
and 3).  If these cells expressed high levels of avb5 integrin, they could be
efficiently transduced by the RGD-4C Ads AdE and AdK, yielding
enhancements of nearly two logs compared to the control AdZ.  This was
observed with primary fibroblasts (Fig.!2A), and a panel of different melanoma
cells (Fig.!2B-D and Fig.!3A).  The transduction boosts of the RGD-4C Ads
strictly depended on the multiplicity of infection in the range of 1 to 100.
M950710 cells which expressed low levels of avb5 integrin exhibited lowest
transduction increase, with a maximal 27-fold.  The transduction increases
were blocked to 80% by soluble RGD-peptides, when compared to control
RGE-peptides, indicating specificity, as shown for the M950504 melanoma
cells (Fig.!3B).  Note, however, that the RGE peptides had a slight enhancing
effect compared to untreated cells.  The underlying reason for this effect is
unknown, but we have observed this effect also with the other RGD-modified
Ads and also the control AdZ (data not shown).  All the other RGD-modified
vectors (AdD, AdF, AdG, AdH and AdI) only marginally increased the eGFP
Nagel et al.
18
expression levels as compared to AdZ or had even slightly lower efficiencies
than AdZ (Fig.!2A-D).  The low levels of transductions were not inhibited by
soluble RGD peptides, except for AdI, where RGD peptides resulted in 35%
inhibition (not shown).
It is well known that most hematopoietic cells are largely resistant to
species!C Ad infections due to lack of CAR and appropriate integrins23,24,32.
Our results of RGD-4C Ad transduction of CAR-less Daudi lymphoma cells
and hematopoietic U937H cells were in agreement with this notion, and the
absolute eGFP expression levels were even a few fold lower than with the
CAR-less non-hematopoietic melanoma cells and fibroblasts.  The eGFP
expression in Daudi cells increased 76-fold and 313-fold when using RGD-4C
AdE and AdK, respectively, whereas for U937H cells, expression was
augmented by 38-fold and 150-fold, respectively (Fig.!4).  All the other
mutants including AdCMV-eGFP-I, demonstrated only low increase,
maximally 2.3-fold.  However, in contrast to nonhematopoietic cells, the high
AdE and AdK mediated transduction of Daudi and U937H cells did not
correlate with the levels of avb5 integrin (Table!4), implicating additional RGD-
binding receptors.  Otherwise, despite expression of avb3 integrin in mature
(day 10) monocyte-derived dendritic cells, such cells remained highly resistant
to all of our RGD-Ads.  The latter result was, however, different from another
study53, which found an enhanced transduction of dendritic cells by RGD-4C
Ad but was also using a different protocol, including a different cytokine mix
and different timing to generate the dendritic cells.  This is known to crucially
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affect the differentiation of dendritic cells54.  Further the THP-1, HL-60 or
U937D hematopietic cells lacking both CAR and most av integrins (see
Table!4, and 55,56) were largely resistant to the RGD-Ad transductions.
It is interesting to note that the AdK was slightly more potent than AdE (2- to
3-fold) in all the CAR-less av integrin-positive cells that we have tested.  This
may suggest that the inserted RGD-motif of AdK could be better accessible
for integrin interactions than the RGD-motif of AdE replacing parts of the HI-
loop.  Taken together, all five CAR-negative adherent cells and two
nonadherent hematopoietic cells were efficiently and specifically transduced
with the RGD-4C containing AdE and AdK.  However, 5- to 10-fold higher
amounts of AdE and AdK were necessary to get transgene expressions
comparable to CAR-expressing cells (for comparison see Fig.!1A and
Fig.!2B).  This suggests that CAR targeting is more efficient than targeting
RGD receptors, which was confirmed by the observations that the RGD-Ads
did not increase the transduction of CAR-positive cells, in agreement with
published data57.
RGD-4C Ad specifically targets the avb5 integrin of CAR-negative cells
Integrins are major receptors of RGD-based ligands10.  We therefore analysed
the binding of radiolabelled RGD-4C AdE, RGD-4C AdK and wild type fiber
AdZ to CAR-positive cells and to CAR-negative melanoma and lymphoma
cells in the presence and absence of soluble RGD-competitor peptide and
adhesion-blocking anti-integrin antibodies.  The optimal concentrations of
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these inhibitors were previously determined by dose-escalation experiments
(results not shown) and used as indicated in Materials and Methods.  Upon
cold incubation (to prevent virus internalisation), about 3% of the [35]-S
methionine labelled AdE, AdK or AdZ bound specifically to A549 cells positive
for CAR and avb5.  This binding was in the very same range as determined
previously with wild type Ad2 to HeLa cells58.  It was largely blocked by the
soluble CARex-Fc protein which has earlier been shown to inhibit virus
binding to cell surface CAR45 but not by control CTLA4-Ig protein (not shown).
In contrast, soluble RGD-peptides or anti-integrin antibodies (see Table!2)
had no effect on AdK binding (not shown), confirming the dominant role of
CAR over integrins in epithelial target cells.
With the CAR-negative primary melanoma cultures M950504, M960104,
M961205 and M95071033, between 0.7 to 2.5% of the input AdE and AdK was
cell-bound, whereas less than 0.07% of the input AdZ control virus bound to
these cells.  Binding of AdK (but not AdZ) to M950504 and M950710
melanoma cells was strongly blocked by soluble RGD-peptides (94%
inhibition) or soluble CARex-Fc (93% inhibition, see Fig.!5A and B) whereas
irrelevant glutathion peptide and CTLA4-Ig protein had no effect, indicating
that AdK attached to cells via its constrained RGD-4C of the fiber knob
domain.  We next employed function-blocking anti-integrin antibodies to
discern if AdK bound to surface integrins.  The anti-avb5 and the anti-av
antibodies P1F659 and 17E660 reduced virus binding in the cold by about 80%
and the non-function blocking anti-b5 antibody B5-IA961 had the same effect
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(Fig.!5A).  Importantly, function-blocking anti-avb362, b1, a5, a6 or a IIbb3
antibodies did not affect AdK binding to M950504 cells, although these cells
expressed significant amounts of b1 and a5 integrins and low but detectable
amounts of avb3, a6 and aIIbb3 integrins (Table!3).  We obtained the same
results also with the M960104 and M961205 cells, which expressed slightly
higher amounts of the same integrins as the M950504 cells (not shown).  In
contrast, the melanoma culture M950710 expressing very low levels of avb3
and avb5 integrins was resistant to all the antibodies, including an irrelevant
control antibody E12/4, that we have tested in AdK binding assays (Fig.!5B).
We further tested binding of AdE and AdK to the CAR-negative, weakly avb5-
positive Daudi and U937H cells and obtained significant binding in the range
of 0.7% and 1.1%.  Binding of control AdZ was insignificant (<!0.007%).  AdK
binding was effectively inhibited by soluble RGD or CARex-Fc peptides but
none of the anti-integrin antibodies, including avb3 specific antibodies,
affected AdK binding, although avb3 integrin was abundantly present on
Daudi cells (Table!4).  This suggests that in the absence of avb5 integrin, yet
other RGD-binding cell surface receptors can be targeted by the constrained
RGD-4C of AdK, but these targets are unlikely to comprise the avb3 integrin
or other RGD-binding integrins composed of either av, a5, a6, b1, b3 and b5
subunits.
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Discussion
A variety of genetic modifications of Ad capsid proteins have retargeted Ad
vectors to cells of interest and thus enhanced the transduction of a number of
CAR-deficient cell types in vitro, including primary human fibroblasts63,
endothelial cells41,63, smooth muscle cells42,63, glioblastoma63, macrophages
and T cells40, acute myeloid leukaemic cells64, myeloma cells65 and ovarian
cancer cells41.  In some cases, vector binding could be uncoupled from
internalisation, but internalisation itself is often crucially linked to cell activation
and subsequent steps of entry, such as endosome escape and nuclear
targeting (reviewed in6).  The receptor responsible for stimulating endocytosis
of species!C Ad vectors has been identified as avb3 and avb5 integrins5.
Subsequently, additional a5b1 and avb1 integrin coreceptors were found11,13.
These integrins activate the target cell upon binding the RGD-motif of the
capsid protein penton base.  In the case of avb5, this appears to require a
precise spatial arrangement of the integrins43.  Since the affinity of penton
base to avb3 and avb5 integrins is rather low (in the range of hundred
nanomolar5), the primary receptor CAR is crucial for infection3.  Accordingly,
CAR-deficient cells are generally refractory to infection and transduction with
therapeutic Ad vectors.
Here we generated and tested a series of seven fiber HI-loop-modified Ads in
order to directly target integrins.  The HI-loop of the fiber knob was chosen as
an engineering site, since it is exposed towards the outside and not directly
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involved in homotypic fiber contacts and CAR binding66-68.  Of the seven RGD-
fiber modified Ads that we have generated here, only the RGD-4C Ads
(designated here AdE and AdK) and to a lower extent AdI, harbouring three
simple RGD-motifs, were able to enhance transduction in an RGD-dependent
manner.  The better performance of the RGD-4C Ads was most likely due to
the disulphide-constrained configuration of this high affinity peptide.  Three
different versions of RGD-motifs were reported in the literature to be
successfully integrated into Ad fiber and enhance transduction.  These
included the above mentioned RGD-4C nonapeptide, which was either
incorporated into the fiber HI loop41 or into the fiber C-terminus40, a linear
tripeptide RGD incorporated in the C-terminus of a de-knobbed fiber
consisting of seven shaft repeats followed by a heterologous trimerisation
motif and a spacer sequence69, and the RGD-motif of penton base
incorporated into the HI loop together with flanking sequences on both sides70.
Using the same penton base RGD motif in combination with short flanking
sequences, we could not detect any significant improvement of gene transfer
with the AdD.  Only a few fold enhancements70 was reported when using more
extended flancing sequences.  Similarly another RGD-motif, (GRGDTF)3 was
introduced at the C-terminus of fiber but did not increase the delivery to
integrin-expressing cells relative to an unmodified vector40, in agreement with
our results.  Together, these data show that a linear or little constrained RGD
may not adopt the optimal conformation to activate integrins.  In addition, our
data show that a replacement of the HI loop with the RGD-4C motif is feasible
although it weakly decreased the transduction efficiency compared to the
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inserted RGD-4C version.  It is possible that flanking sequences are important
to enhance the exposure of peptide motifs integrated in the HI loop and that
for each type of targeting peptide, an individual flanking sequence is required
for optimal interactions with the target receptor.
Using function blocking antibodies and quantitative virus binding experiments
together with transduction experiments in a variety of CAR-deficient cells, we
demonstrate that only the RGD-4C Ads are truly targeted to cell surface
integrins.  The transduction experiments were conducted with two types of
CAR-negative cells, nonhematopoietic and hematopoietic cells.  The
transductions of the CAR-negative primary melanoma cell cultures M950504,
M961205 and M960104 with AdK indicated an important role of avb5
integrins.  However, in cells with very low levels of avb5, e.g. in M950710,
Daudi or U937H lymphoma cells, binding of the RGD-4C Ad was not inhibited
by anti-avb5 integrin antibodies but it was still sensitive towards soluble RGD-
peptide competitor, indicating that additional RGD-binding receptors on these
cells can serve as an Ad transduction receptor.  Based on our experiments
involving the two function blocking anti-integrin antibodies for av and avb3, we
are suggesting that avb3 integrin is not involved in the transduction
mechanism of RGD-4C Ads.  That the RGD-4C Ads did not bind avb3 integrin
is somewhat surprising, since it was originally demonstrated to have high
affinity to avb3 and avb5 integrins using phage display screens39.  Likewise,
recombinant extracellular domains of avb3 bound to immobilised RGD-4C-
modified fibers or to whole RGD-4C Ad in vitro41.  It is possible that our RGD-
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4C Ads fail to bind the cell-associated avb3 integrin because the constrained
RGD-conformation is different from the soluble RGD-peptide and because the
full length transmembrane integrins have a narrower binding specificity than
the soluble domains.  Accordingly, our results agree with a recent study
showing that preferentially avb3-binding peptides do not compete with the
RGD-4C Ad71.  Alternatively, it is possible that on the cells that we have tested
here, the avb3 integrin lacks a particular cofactor that renders it competent for
binding the RGD-modified Ads.  Based on the results using one function
blocking integrin antibody each for a5, b1 a6 aIIbb3, we suggest that these
integrin subunits do not serve as efficient RGD-4C targets.  However, use of
additional integrin antibodies are warranted to confirm this findings.
Furthermore, it remains to be tested whether non-RGD-binding integrins, such
as amb2 (CD11b), aLb2 (CD11a) and aXb2 (CD11c)55 are responsible for the
tropism of RGD-4C Ads or if even non-integrin receptors are involved.
Our results support the notion that the RGD-4C fiber HI-loop modified Ad
vectors specifically target the avb5 integrin, but that also additional, so far
undefined integrins, are likely to be targeted by these vectors.  Although these
results add further weight to the proposal that RGD-modified Ads may be
locally administered for cancer therapies, targeting for example CAR-negative
ovarian cancer72, we must add a note of caution.  Given the residual strong
CAR-binding of the RGD-4C Ad vectors (see also 57) and also the expanded
tropism, extreme care should be taken before using these vectors in human
therapies.  In particular, not all the RGD-targets of this virus are fully
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characterised, raising the concern of unwanted transduction events.  Indeed,
when Mizugucchi et al analysed their RGD-4C Ad, they detected a so far
unrecognised hemagglutination activity of mouse erythrocytes73, which may
be responsible for the reduced transduction of liver cells when using this virus
in systemic administrations.  Although this agglutination activity was not found
with human erythrocytes, these results illustrate that we do not fully
comprehend the underlying events of systemic Ad transductions.  The RGD-
4C modified Ads described here have a significant potential to transduce
CAR-less hematopietic and also nonhematopoietic cells, but their preferred
use may be together with additional strategies, such as transcriptional
restrictions and selective deletions of viral genes and CAR binding ablations
of the fiber knob.
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Figures and tables
Fig.!1.  Ad-mediated reporter gene expression in CAR-positive, adherent
nonhematopoietic cells.  Human A549 (A) and primary HUVEC (B) were
incubated with RGD-fiber-modified AdCMV-eGFP-D, -E, -F, -G, -H, -I, -K or wt
control AdCMV-eGFP-Z at MOI's of 0.1, 1, or 10.  Two days post infection,
eGFP expression was analysed.  Results are reported as the averages of
triplicate determinations of eGFP mean values including standard deviations.
Fig.!2.  Ad-mediated reporter gene expression in CAR-less, adherent
nonhematopoietic cells.  Primary fibroblasts (A) or primary melanoma cell
cultures M960104 (B), M961205 (C) and M950710 (D) were incubated with
RGD-fiber-modified AdCMV-eGFP-D, -E, -F, -G, -H, -I, -K or wt control
AdCMV-eGFP-Z at MOI's of 1, 10, or 100 and analysed as in Fig.!1.
Fig.!3.  Ad-mediated reporter gene expression in CAR-less, adherent
melanoma cell cultures M950504.  (A) The cells were incubated with RGD-
fiber-modified AdCMV-eGFP-E, -K or wt control AdCMV-eGFP-Z at MOI's of
1, 10, or 100 (A) and analysed as in Fig.!1.  (B) The cells were incubated with
RGD-fiber-modified AdCMV-eGFP-E, -K or wt control AdCMV-eGFP-Z at an
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MOI of 50 in the absence or presence of either the linear control peptide
GRGESP or the specific peptide GRGDSP.
Fig.!4.  Ad-mediated reporter gene expression in CAR-less, hematopoietic
cells.  Daudi (A) and U937H (B) cells were incubated with RGD-fiber-modified
AdCMV-eGFP-D, -E, -F, -G, -H, -I, -K or wt control AdCMV-eGFP-Z at MOI's
of 1, 10, or 100 and analysed as in Fig.!1
Fig.!5.  Attachment of RGD-4C fiber modified virus AdCMV-eGFP-K to CAR-
less nonhematopoietic cells. 2-5x105 M950504 cells (A) and M950710 cells
(B) were mixed on ice with the indicated specific inhibitors or controls,
followed by addition of [35S]methionine-labelled virus.  After incubation for 2!h,
the cells were washed and cell-associated radioactivity was determined.  The
data were normalised to the amounts of virus bound in absence of inhibitors
and are represented as average of triplicate determinations including standard
deviations.  The asterisks indicate the level of significance with p < 0.05 and
bold indicates function blocking antibodies.
Fig.!6.  Attachment of RGD-4C fiber modified virus AdCMV-eGFP-K to CAR-
less hematopoietic cells.  5x105 Daudi cells (A) and U937H cells (B) were
mixed on ice with the indicated specific inhibitors or controls, followed by
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addition of [35S]methionine-labelled RGD-4C fiber modified virus and analysed
as for Fig.!4.  Mix indicates a combination of antibodies B5-IA9 (b5), mAb11
(a5), ) and mAb13 (b1).
Table 2: Antibodies used for characterization of integrins
Antibody Specificity Function
blocking
Reference
Ab
Reference
functionality
Supplyer
LM609 avb3 yes 74 62,74 D. Cheresh, Scripps
Research Institute, La
Jolla, USA
P1F6 avb5 yes 62 59 D. Cheresh
LM142 av (CD51) no 74 62,74 D. Cheresh
17E6 av CD(51) yes 60 60 S .  G o o d m a n ,
MERCK, Darmstadt,
Germany)
mAb 13 b1 (CD29) yes 75 75 K .  Y a m a d a ,
L a b o r a t o r y  o f
Developmental
B i o l o g y ,  N I H ,
Bethesda, USA
AP3 b3 (CD61) no 76 76 P. Newman, Blood
Research Institute,
Milwaukee, USA
B5-IA9 b5 no 61 61 D. Cheresh
mAb 11 a5 (CD49e) no K. Yamada
mAb 16 a5 (CD49e) yes 75 75 K. Yamada
GoH3 a6 (CD49f) yes 77 78 Serotec,  Oxford ,
United Kingdom
AP2 aIIbb3 yes 79 79 P. Newman
aLb2
(CD11a)
Pharmingen, San
Diego, USA
aMb2
(CD11b)
Pharmingen
axb2
(CD11c)
Pharmingen
E12/4
(control)
CD46 (non
integrin)
80 B.  Rosc ic -Mrk ic ,
University Hospital
Zürich, Switzerland
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